ARTICLE | Clinical News
GVAX cancer vaccine consisting of patients' own tumor cells: Began Phase I trial in the Netherlands, to determine safety and toxicity, and the nature and extent
July 25, 1994 7:00 AM UTC
Somatix Therapy Corp. ( SOMA), Alameda, Calif. Product: GVAX cancer vaccine consisting of patients' own tumor cells, genetically modified to secrete high levels of GM-CSF and irradiated to prevent cel...